Dear Editor, In their letter [1], Ortego-Jurado et al. report results of a prospective study of 61 postmenopausal women on chronic glucocorticoid therapy for mixed systemic autoimmune diseases. The women were being treated with a bisphosphonate as well as vitamin D for secondary osteoporosis. After 1 year, less than half of the patients showed a positive response (no loss of bone mass) with bisphosphonate treatment. This finding is said to be similar to our report [2] and other studies, which indicate that "real world" response to bisphosphonate treatment, may be less significant than that seen in published clinical trials. The role of vitamin D in response to bisphosphonate therapy is an important clinical question. The above study addresses this among women with systemic autoimmune diseases on chronic glucocorticoid therapy-a population quite different from that of our study where women on chronic steroid therapy were excluded. The criteria for non-response was no loss of bone mass after 1 year, which differs from our criteria which also included very low BMD after 24 months, and incident fragility fracture during bisphosphonate treatment, in addition to a >3 % decline in BMD. Furthermore, the mean duration between DEXA scans in our study was 26 months; longer than the 1-year follow-up of this study. Patients in the study by OrtegoJurado et al. may have been categorized differently in terms of response status if a longer follow-up interval was allowed to elapse. Finally, this study reports a single value for the patients' vitamin D level, whereas in our study, we reported the mean of several values over the course of therapy. The effect of vitamin D on bisphosphonate response among patients with chronic autoimmune disease and on chronic glucocorticoid therapy may well be different than that of postmenopausal women on long-term treatment for primary osteoporosis. Vitamin D supplementation may play more of a role in response when observed over a longer period of time. Additional, larger, long-term studies are warranted to further clarify the role of vitamin D in bisphosphonate treatment among women on long-term steroid therapy. 
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